Mythical Foreign Investors Frequently Purchase Stakes at High Prices, Kedapharma's Profit Margin Exceeds 90%, and Promotion Meeting Attendance Significantly Outstrips Industry Peers | IPO Observation
In recent days, Kedapharma Pharmaceutical Co., Ltd. (hereinafter referred to as "Kedapharma") has made new progress in its listing process on the sci-tech innovation board, having submitted a response to the second round of inquiries.
According to the prospectus, Kedapharma is a comprehensive pharmaceutical company specializing in the development, production, and sale of chemical raw materials, chemical preparations, and medical devices for central nervous system diseases.
In the second round of inquiries, the Shanghai Stock Exchange gave particular attention to Kedapharma's profit margin, sales expenses, and foreign capital investors' stake purchase situations...
One: Profit Margin Exceeds 90%, Mythical Foreign Investors Frequently Purchase Stakes at High Prices!
From a business income perspective, Kedapharma's main source of income comes from the development and sale of chemical preparations. In 2020-2022 and the first half of 2023, Kedapharma's business income was RMB 5.57 billion, RMB 6.88 billion, RMB 9.01 billion, and RMB 5.65 billion, with year-on-year growth rates of 9.30%, 23.48%, 4.35%, and 30.24%.
In addition to maintaining stable growth in business income, Kedapharma's net profit also showed a significant increase.
Data shows that in 2020-2022 and the first half of 2023, Kedapharma's net profit was RMB 1.10 billion, RMB 1.47 billion, RMB 2.09 billion, and RMB 1.28 billion, with year-on-year growth rates of 23.41%, 33.81%, 42.47%, and 6.94%.
Kedapharma's net profit margin rapidly increased due to its significant advantage in gross profit margins. In the aforementioned periods, Kedapharma's main business gross profit margin was around 93%...
...